30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Orthopaedic Industry Reaches $49 Billion in 2017

Orthopaedic industry revenue reached $49.3 billion worldwide in 2017 and grew at 3.7%, ~$1.7 billion over 2016, according to our estimates to be published in the ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.

In 2017, the 20 largest orthopaedic device companies—those with revenue above $200 million—posted growth. That’s a statement we haven’t made for at least the last three years, and one we think indicates positive momentum in orthopaedics. What fueled this growth? New product launches, acquisitions and international expansion were the most-cited contributors by company executives.

The Age of Biology Comes to Orthopaedics

In the field of orthopaedic surgery, over the last 100 years we have migrated from therapies based on limb removal to joint replacement to tissue repair, and we are beginning to see clinical solutions for tissue regeneration. These four Rs represent the history and future of clinical orthopaedics.

Orthobiologics: Conversations with CEOs

At AAOS, we sat down with the CEOs of Bioventus and Histogenics to ask about opportunities that their companies are embracing, as well as the health of the orthobiologics market. Both mentioned advancements in therapies demonstrated through clinical trials and outcomes, and both discussed the importance of keeping younger, active patients healthy and mobile. Here we recap a portion of those conversations.

Why One Surgeon Entrepreneur is Focused on MIS, Orthobiologics and UDI

Patrick Sweeney, M.D., is a spine surgeon with a special interest in minimally invasive surgery. He is also Founder and Medical Director of the Center for Minimally Invasive Surgery, an ASC, as well as an inventor/entrepreneur, and founder of a device company and an eHealth entity. We spoke with him about his diverse orthopaedic endeavors.

New Total Knee and Hip Products Focus on Additive, Materials, Robotics

Orthopaedic device manufacturers’ ability to gain market share in the total knee and hip reconstruction spaces will be dependent upon their response to the shift of procedures to ambulatory surgery centers  an uptick in bundled payments and any or all measures focused around cost. That was the message we took away from our conversations at the American Academy of Orthopaedic Surgeons Annual Meeting.

Page Navigation
First